What are the Paris investigations into infant formula?

Growing legal and regulatory scrutiny across markets

French prosecutors in Paris have opened inquiries tied to a series of infant-formula recalls linked to a toxin called cereulide. Several major dairy and food companies are mentioned in the probe, reflecting heightened regulatory concern about the safety and oversight of products intended for babies.

The investigations come amid mounting pressure from families and public-health officials. In France, more than 20 families have taken legal action against authorities, arguing that investigations into the recalls were mishandled. At the same time, regulators in other countries are taking separate actions: Brazil’s health agency recalled a specialized infant product over concerns about iodine and selenium levels, widening the scope of international fallout.

Key points:

• Multiple large manufacturers are implicated in the Paris inquiry, exposing major firms to potential fines or sanctions.
• Families in France have filed lawsuits alleging failures in the official response and oversight.
• Separate recalls and regulatory steps in other countries underscore systemic scrutiny of infant-nutrition safety.

Why it matters: infant formula is a tightly regulated category because of the vulnerability of the consumers. Criminal or administrative findings could lead to penalties, stricter oversight, product reformulations, or changes to how recalls are managed and communicated. The situation also carries commercial risks: affected brands face reputational damage, potential drops in sales, and legal costs. Many questions remain unanswered, including the investigations’ timelines and possible outcomes. Regulators, manufacturers, and consumer advocates will be watching how evidence is gathered and what corrective steps are ordered.